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Abstract
Background: The occurrence of antibiotic resistant Neisseria gonorrhoeae isolates is a serious public health problem
in different corners of the globe. The objective of this study was to analyze the antimicrobial susceptibility pattern
of N. gonorrhoeae in Northwest Ethiopia.
Methods: This was a retrospective study of N. gonorrhoeae isolated from genital swabs of patients referred to the
Amhara Regional Health Research Laboratory between September 2006 and June 2012 in Bahir Dar, Ethiopia. A
structured check list was used to collect socio-demographic and laboratory variables. Data were analyzed using
SPSS software version 16.
Results: Out of 352 genital specimens processed, 29 clinical strains of N. gonorrhoeae were identified. The
percentage of N. gonorrhoeae isolates non-susceptible to ceftriaxone, ciprofloxacin, tetracycline and penicillin G
was 27.8%, 40.9%, 92.6% and 94.4% respectively. Twenty percent of the isolates were found to be non-susceptible
to both ceftriaxone and ciprofloxacin. Non-susceptibility to an injectable cephalosporin and any two of quinolones,
penicillins or tetracyclines was observed in 27.8% of the isolates. The percentage of N. gonorrhoeae which were
non-susceptible to tetracycline or penicillin G was high throughout the study period. However, the percentage of
fluoroquinolone or cephalosporine non-susceptible strains showed an increasing trend.
Conclusions: A high percentage of N. gonorrhoeae isolated from genital specimens in Northwest Ethiopia are
non-susceptible to an injectable cephalosporin and any two of quinolones, penicillins or tetracyclines. Treatment of
gonorrhea in the study area needs to be guided by antibiotic susceptibility testing of isolates.
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Background
Gonococcal infections are the second most common
prevalent sexually transmitted bacterial infections causing
substantial morbidity worldwide each year [1]. In addition
to causing serious complications, gonorrhea is a potent
amplifier of the spread of sexually transmitted HIV [2]
increasing the infective inoculums of HIV in persons
with HIV and gonorrhea co-infection.
Resistance to commonly-prescribed antibiotics of Neisseria
gonorrhoeae is an expanding global problem resulting in
diminishing treatment options for gonorrhea. Loss of
utility of several drugs such as sulfonamides, penicillins and
tetracyclines, for treatment of gonorrhea, were reported
in both developed and developing countries [3,4].
Until recently, quinolones and third-generation cepha-
losporins had activity against N. gonorrhoeae strains that
were resistant to previously used antibiotics such as
sulfonamides or tetracyclines. However, the emergence
and spread of gonococci resistant to the quinolone group
of antibacterials was reported from different corners of
the world [5,6]. Failures of treatment with oral third-
generation cephalosporins for infection with gonococci
or raised minimum inhibitory concentrations to them
have been documented in different continents including
Europe, Asia and North America [7-10].* Correspondence: marthatib@yahoo.com1Department of Medical Microbiology, Immunology and Parasitology, Bahir
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Although individual country-based intermittent analyses
about drug resistant gonococci have been published from
some countries, information about the exact magnitude
of multidrug resistant (MDR) N. gonorrhoeae is generally
lacking for most of African countries including Ethiopia.
The current treatment guidelines in Ethiopia, and some
other African countries, suggest the syndromic case man-
agement for all sexually transmitted infections (STIs)
including gonorrhea based on the WHO recommenda-
tion [11].
With the occurrence of resistance to commonly pre-
scribed antibiotics in both developed and developing
countries, an updated knowledge of the prevailing sus-
ceptibility patterns of gonococci in Ethiopia is important
for the proper selection and use of antimicrobial drugs
as well as for the development of an appropriate pre-
scription policy. This study was aimed to investigate the
antibiotic susceptibility patterns of N. gonorrhoeae iso-
lated from genital swab of patients seen in the Amhara
Regional Health Research Laboratory (ARHRL), Bahir
Dar, Ethiopia.
Methods
Study design and period
In this retrospective study, genital specimen analysis
data from bacteriology laboratory registers, which were
documented between September 2006 and June 2012 in
the ARHRL, Bahir Dar Center, Ethiopia was used.
Study area
The ARHRL Bahir Dar Center is the main referral
laboratory in the Amhara National Regional State (ANRS).
The laboratory is located in Bahir Dar, the capital of
the ANRS. Patients get referred to this laboratory from
both private and government owned health facilities
located in the administrative divisions in the ANRS as
well as from adjacent regions in the country.
Source population, study participants
The source populations were patients in the ANRS who
were referred to the ARHL Bahir Dar Center for la-
boratory work up. All genital specimen analyses reports
between September 2006 and June 2012 were included
in this study.
Laboratory methods
As part of the routine bacteriologic investigations at
ARHRL, all genital specimens were plated onto modified
Thayer Martin media immediately after collection in the
laboratory and incubated at 37°C in 5% CO2. The plates
were read daily for up to 72 hours and isolates were
identified by conventional phenotypic and biochemical
methods. Gram negative diplococcic which were oxidase
and catalase positive were considered as N. gonorrhoeae.
Susceptibility testing was performed by Kirby-Bauer disc
diffusion method using penicillin G (10 ug), tetracycline
(30 ug), ciprofloxacin (5 ug) and ceftriaxone (30 ug).
CLSI guidelines were used for interpretation of zones of
inhibition and quality control.
Data extraction methods
A structured check list was used to collect socio-demo-
graphic and laboratory data such as the antibiotic suscep-
tibility test results and year of test. The laboratory records
did not specify the type of symptoms or any other clinical
information.
In order to analyze trends of antibiotic resistance by
N. gonorrhoeae, the study period was divided into three
categories, i.e., September 2006 – August 2009, September
2009 – August 2011 and September 2011 - June 2012.
Data quality management, processing and analysis
Data were double-entered using Epi info version 3.5 and
analyzed using SPSS software version 16.
Operational definitions
Non-susceptible N. gonorrhoeae isolates were defined as
those that are not sensitive to the antibiotic tested for
susceptibility, i.e., those isolates exhibiting resistance or
intermediate resistance.
Dual non-susceptibility: non-susceptibility to any two
of the antibiotics tested for susceptibility.
Multi Drug Non-susceptibility: Combined non-sus-
ceptibility to an injectable cephalosporin and any two of
quinolones, penicillins or tetracyclines.
Ethical considerations
Ethical approval to conduct the study was obtained from
the research and technology transfer core process of the
ANRH bureau. Permission to conduct the study was
granted from the ARHRL, Bahir Dar center.
Results
Between September 2006 and June 2012, 352 genital
specimens were analyzed in ARHRL, Bahir Dar Center
by bacterial culture following the standard operating
procedures. The mean age of the participants was
28.1 years (SD = 8.4), with female to male ratio of 1.1. As
indicated on Table 1, there were 29 clinical strains of N.
gonorrhoeae isolated and processed for susceptibility
testing during the study period.
Table 2 shows the antibiotic susceptibility pattern of
the N. gonorrhoeae isolates. In toto, as much as 27.8% of
the isolates were non-susceptible to ceftriaxone. Non-
susceptibility to ciprofloxacin was noticed in 40.9% of
the isolates. High percentage of non-susceptibility was
observed against penicillin G (94.4%) and tetracycline
(92.6%). Non-susceptibility to an injectable cephalosporin
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coupled to any two of penicillins, ciprofloxacin or tetra-
cycline was identified in 27.8% of the isolates. Dual non-
susceptibility to ceftriaxone and ciprofloxacin was noticed
in 20% of the isolates, all of which were documented
between Sept. 2011 and June 2012.
The percentage of isolates non-susceptible to cipro-
floxacin recorded between September 2009 to August
2011 was 11.1%. Between September 2011 to June 2012,
the percentage of non-susceptibility documented against
ciprofloxacin was 77.8%. Non-susceptibility to ceftriax-
one was demonstrated by 20% of the isolates between
September 2006 and August 2009 while it was 80%
between September 2011 to June 2012. The percentage
of N. gonorrhoeae isolates which were non-susceptible to
tetracycline or penicillin G was high over the past 6 years.
However, percentage non-susceptibility to fluoroquinolones
or cephalosporins showed an increasing trend during the
study period, as indicated on Table 3.
Discussion
For the first time, this study reported an evidence of
reduced susceptibility to common and new generation
antibiotics of N. gonorrhoeae isolates in Northwest Ethiopia.
It also revealed increasing trend in percentages of cephalo-
sporin or fluoroquinolone non-susceptible isolates while
that of old, inexpensive antibiotics such as penicillin and
tetracycline was maintained at a high level.
Although the main stay of management of discharge
syndromes in the study area is the syndromic approach,
the number of isolates being sent for bacteriological
analysis showed an increasing tendency with time. As
opposed to the etiological approach which uses labora-
tory tests to identify the causative agents of STIs, the
syndromic approach leads to immediate treatment for
possible causes of one of seven STI syndromes based
on symptoms only [12]. This indicates a gradual shift to
the etiologic approach of diagnosis of gonorrhea. The
occurrence of N. gonorrhoeae isolates non-susceptible to
the available antibiotics could be the underlying factor
to the increased request for the exact identification of
etiologic agents and determination of their susceptibility
patterns.
Table 1 Number of specimens and N. gonorrhoeae
























122 13 10.7% (5.8%, 17.5%)
Total 352 29 8.2% (5.6%, 11.6%)
Table 2 Antibiotic susceptibility profile of N. gonorrhoeae
isolates from September 2006 to June 2012, ANRS,
Ethiopia




Ceftriaxone 27.8 (9.7, 53.5)
Penicillin G 94.4 (72.7, 99.9)
Tetracycline 92.6 (75.7, 99.1)
Ciprofloxacin 40.9 (20.7, 63.6)
Ceftriaxone and Penicillin G 35.7 (12.8, 64.9)
Ceftriaxone and Tetracycline 31.3 (11.1, 58.7)
Ceftriaxone and Ciprofloxacin 20 (4.3, 48.1)
Penicillin G and Tetracycline 87.5 (61.7, 98.4)
Penicillin G and Ciprofloxacin 66.7 (34.9, 90.1)
Tetracycline and Ciprofloxacin 38.1 (18.1, 61.6)
Multi drug non-susceptibility 27.8 (9.7, 53.5)
Other triple non-susceptibility 63.6 (30.8, 89.1)
All four drugs non-susceptibility 27.3 (6.0, 61.0)
Table 3 Trends in antibiotic non-susceptibility of clinical
N. gonrrhoeae isolates in the Amhara regional health











Ceftriaxone 20 (1/5) 0 80 (4/5)
Penicillin G 23.5 (4/17) 17.7 (3/17) 58.8 (10/17)
Tetracycline 28.0 (7/25) 24.0 (6/25) 48.0 (12/25)
Ciprofloxacin 11.1 (1/9) 11.1 (1/9) 77.8 (7/9)
Ceftriaxone and
Penicillin G
20 (1/5) 0 80 (4/5)
Ceftriaxone and
Tetracycline
20 (1/5) 0 80 (4/5)
Ceftriaxone and
Ciprofloxacin
0 0 100 (3/3)
Penicillin G and
Tetracycline
21.4 (3/14) 14.3 (2/14) 64.3 (9/14)
Penicillin G and
Ciprofloxacin
0 12.5 (1/8) 87.5 (7/8)
Tetracycline and
Ciprofloxacin
12.5 (1/8) 0 87.5 (7/8)
Multi drug non-
susceptibility
20 (1/5) 0 80 (4/5)
Numbers in each cell in the body of the table are: Percent (Number of
non-susceptible isolate/Total isolates tested for the antimicrobial agent in that
year band).
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In this study, a high level of non-susceptibility to new
generation antibiotics such as ciprofloxacin and ceftriax-
one was noticed. The high proportion of fluoroquinolone
non-susceptibility by N. gonorrhoeae is coherent with
reports from many countries including South Africa,
Kenya and the Southeast Asia region [13-15]. The reason
for this consistency may be the global nature of gonorrhea.
Those infected in one part of the world will often spread
the infection to those living elsewhere if ineffective treat-
ment is used. However, the roles of spontaneous mutation
and the abilities of bacteria to adapt to different envir-
onmental situations to the occurrence of MDR N.
gonorrhoeae in the study area cannot be ruled out.
However, low levels of non-susceptibility to ciprofloxa-
cin were reported from a multi-centered study conducted
in Central African Republic, Cameroon and Madagascar
[16]. The inconsistency of our finding with these reports
may be the difference in time frame between the studies.
With the introduction of syndromic management for
STIs [12], the use of fluoroquinolones and cephalospo-
rins is practiced in a standardized fashion. However,
this creates a selective advantage for the organisms
resistant to these medications [17]. As a result, N.
gonorrhoeae having reduced susceptibility to such drugs
would occur. Use of fluoroquinolones and cephalosporins
for treatment of other conditions may lead to sensitization
of the N. gonorrhoeae isolates in asymptomatic patients
with gradual selection of drug resistant strains and eventu-
ally clinically significant resistance.
The high levels of tetracycline and penicillin G non-
susceptibility reported in this study parallel earlier experi-
ence of other countries such as Malawi and Kissumu,
Kenya [3,4]. As Gedebou M and Tasew A had reported
the presence of a relatively lower level of resistance of N.
gonorrhoeae to tetracycline (8%) and Penicillin (41%) in
Ethiopia three decades ago [18], the current magnitude
of reduced susceptibility to these drugs seems to have
developed gradually. Also a study to determine the suscep-
tibility patterns of N. gonorrhoeae isolates in Northwest
Ethiopia had reported, in 2001, lower resistance rates to
penicillin G (85.2%), tetracycline (29.6%) and cefrtriaxone
(4.2%) [19], thus supporting the gradual nature of the
condition.
The finding of the presence of N. gonorrhoeae having
reduced susceptibility to an injectable cephalosporine
and any two of quinolones, penicillins or tetracyclines in
the study area is coherent with the reports from other
areas such as the Western Pacific region [20]. Based on
the WHO recommendation that an antimicrobial asso-
ciated with a resistance of ≥ 5% of strains should be
abandoned [11], the use of cephalosporins, ciprofloxacin,
penicillin G or tetracyclines for the treatment of gonor-
rhea in the general population in the ANRS would be
questionable.
Currently, the Centers for Disease Control and Preven-
tion (CDC) recommends dual therapy with ceftriaxone
(250 mg intramuscularly as a single dose plus either
azithromycin 1 gram orally as a single dose or doxycycline
100 mg orally twice a day for 7 days as the most effective
treatment for uncomplicated gonorrhea [21]. Even though
it is not possible to have data about the susceptibility
patterns of N. gonorrhoeae isolates for doxycycline in the
study area, it is theoretically known that microorganisms
that have become insensitive to one tetracycline invariably
exhibit cross resistance to other tetracyclines due to trans-
missible plasmids [22]. Therefore, based on the finding
that there is high proportion of ceftriaxone-tetracycline
dual non-susceptibility, the use of ceftriaxone-doxycycline
combination for the treatment of gonorrhea in the study
area needs caution.
The results from this study are alarming because this
level of non-susceptibility to common and new generation
antibiotics is being reported in a setting where there are
only few alternatives for the management of gonorrhea.
Since antibiotic treatment is the foundation of gonorrhea
management, the emergence of N. gonorrhoeae having
reduced susceptibility to the available and affordable
antibiotics can be associated with an increase in the
risk of complications of infection, hence a challenge to
clinicians. The occurrence of untreatable gonorrhea in
a country that already has diseases such as tuberculosis,
HIV and malaria [23] as the public health priorities is an
additional burden. It would threaten effective disease
control because there are no effective antimicrobial
resistance surveillance programs for N. gonorrhoeae in
the ANRS as well as in other parts of Ethiopia. The im-
pact on HIV transmission could also be very serious be-
cause in the ANRS the prevalence of HIV is high [24].
The findings in this report are subject to the following
limitations. First, the data presented here are based on
results reported on laboratory registers; due to the
retrospective nature of the study, documentation prob-
lems are an issue. Second, susceptibility testing was
done by the Kirby-Bauer disc susceptibility testing
method, which is unsuitable for the laboratory differen-
tiation of partially resistant from fully resistant strains
of N. gonorrhoeae [25], thus necessitating the strict use
of the word ‘non-susceptible’ instead of ‘resistant’. Third,
data available only include results from genital gonococcal
isolates among patients who were referred for laboratory
analysis. As patients who respond to empiric treatment
are not sent for laboratory analysis, subjects included in
this study are those who were already exposed for different
antibiotics. That individuals at risk for the occurrence of
antibiotic resistance are the study subjects makes selection
bias unavoidable.
The other is the small number of isolates documented
and analyzed over the years. This was mainly related to
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the policy in Ethiopia which recommends syndromic case
management of STI cases as opposed to the etiologic
approach which would have lead to laboratory analysis
of more isolates and determination of drug susceptibility
patterns. However, in light of similar trends in other
regions of the world, the patterns observed in this study
coupled to the ability of N. gonorrhoeae to develop re-
sistance are concerning enough.
Conclusions
High proportion of N. gonorrhoeae isolated from genital
specimens in the ANRS are non-susceptible to old and
new generation antibiotics including to a combination of
an injectable cephalosporin and any two of quinolones,
penicillins or tetracyclines. In view of this, the national
guideline for management of gonorrhea needs to be
urgently reviewed. The diagnostic approach needs to be
modified to include determination of susceptibility patterns
of N. gonorrhoeae isolates. Clinicians need to consider
treatment of gonorrhea based on individual susceptibility
patterns instead of the routine empirical treatment of
discharge syndromes. A strategy should be established
to rapidly detect patients diagnosed with gonorrhea
who experience a clinical treatment failure following
treatment with the recommended antibiotics. Current
treatment recommendations for gonorrhea in the study
area need to be validated and updated. Protocols for
management of gonorrhea treatment failures need to
be put in place. Antimicrobial resistance surveillance
program needs to be launched in ANRS in order to obtain
antimicrobial resistance profiles in a timely manner and
with sufficient clinical and epidemiological information.
Further studies with determination of MIC need to be
conducted in the study area in order to determine the
exact level of bacterial resistance.
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